echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Gut: Rifupin is used to prevent the recurrence of standard treatment for refractive lysergic bacillus infection

    Gut: Rifupin is used to prevent the recurrence of standard treatment for refractive lysergic bacillus infection

    • Last Update: 2020-06-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    About a quarter of patients relapse after initial treatment with Cdifficile infection (CDI)A single-center pilot study showed that the use of 'follow-up' riflepine therapy reduced recurrenceOur goal is to assess the efficacy of lifupin therapy in preventing recurrencea multi-station, parallel group, randomized, placebo-controlled trial, in which patients aged up to 18 years of age were recruited and treated with methazole or vancomycin, immediately after CDI resolutionThe subjects received 400 mg of liofpine three times a day, three times a day, for 2 weeks, then reduced to 200 mg, three times a day, and then for 2 weeks, or the same placeboThe main endpoint was CDI recurrence within 12 weeks of joining the group151 participants were randomly assigned to liverpine or placebo between December 2012 and March 2016130 people obtained the main outcome dataThe average age is 71.9 years (SD 15.3)The recurrence rate was 29.5% (18/61) at 12 weeks, while in the participants who received the placebo, the recurrence rate was 29.5% (18/61) in 12 weeks, while in the participants who received TheRfupin, the recurrence rate was 15.9% (11/69), with a difference of 13.7% (95% CI-28.1% to 0.7%, P.06)The risk ratio is 0.54 (95% CI 0.28 to 1.05, p-0.07)During the six-month safety follow-up period, 9 participants in each group died (12%)The rate of adverse events between groups is similarAlthough the 'follow-up' of CDI seems to halve the recurrence rate, in this group of frail elderly patients, we failed to meet our recruitment targets, so The accuracy of Rifping's estimates is not accurateA meta-analysis, including previous trials, suggests that lifupin may be effective;
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.